Preclinical drug development must consider the impact on metastasis
Data(s) |
2009
|
---|---|
Resumo |
Recently, two landmark reports on antiangiogenic therapy were published: Paez-Ribes and colleagues and Ebos and colleagues . The Board of the Metastasis Research Society (MRS) congratulates the authors for their informative articles that help to explain the puzzle of why antiangiogenic agents have had a relatively minor or no significant impact on patient survival. Using four model systems and several different strategies, these researchers showed that inhibition of angiogenesis reduced primary tumor growth and microvessel density in keeping with many earlier reports, but strikingly, accelerated invasion and metastasis. |
Identificador | |
Publicador |
American Association for Cancer Research |
Relação |
DOI:10.1158/1078-0432.CCR-09-1363 Steeg, Patricia S., Anderson, Robin L., Bar-Eli, Menashe, Chambers, Ann F., Eccles, Suzanne A., Hunter, Kent W., Itoh, Kazuyuki, Kang, Yibin, Matrisian, Lynn M., Sleeman, Jonathan P., Theodorescu, Dan, Thompson, Erik W., & Welch, Danny R. (2009) Preclinical drug development must consider the impact on metastasis. Clinical Cancer Research, 15(14), pp. 4529-4530. |
Fonte |
Faculty of Health |
Tipo |
Journal Article |